Single Nucleotide Polymorphisms and AMD in Older Women
Principal Investigator
Anne Coleman, MD, PhD
University of California, Los Angeles
Los Angeles, CA, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
April 01, 2007 - March 31, 2009
Grant ID
M2007059
Goals
These experiments seek to determine whether genes related to bone metabolism are associated with risk of AMD
Summary
Age-related macular degeneration (AMD) is a leading cause of vision loss and blindness in persons 65 years of age and older in the developed world. The cause of AMD is not known; however, it is believed that a combination of genetic and environmental factors is responsible for the majority of cases. Therefore, studies involving genes relevant to eye tissues and function, and determining if their effects are modified by the presence of other AMD risk factors such as smoking. This may reveal important information regarding the cause of this important disease. Some of our preliminary research suggests that bone disease and AMD may have common risk factors. Therefore, genes relevant to bone disease and metabolism may be associated with AMD risk. Using data from the Study of Osteoporotic Fractures, the goals of our study are to determine whether variations in 15 genes related to bone metabolism and expressed in eye tissues are associated with incident AMD in women 75 years of age and older and whether genetic effects may be modified by environmental risk factors for AMD such as smoking, nutritional factors, or reproductive hormone exposures.
Grants
Related Grants
Macular Degeneration Research
The Novel Role of an Intracellular Nuclear Receptor in AMD Pathogenesis
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Neetu Kushwah, PhD
The Novel Role of an Intracellular Nuclear Receptor in AMD Pathogenesis
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Neetu Kushwah, PhD
Macular Degeneration Research
Exploring How NRF2 Protein Reduces RPE Cell Damage by Cigarette Smoke
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Krishna Singh, PhD
Exploring How NRF2 Protein Reduces RPE Cell Damage by Cigarette Smoke
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Krishna Singh, PhD
Macular Degeneration Research
The Development of a Transplant-Independent Therapy for RPE Dysfunction
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Shintaro Shirahama, MD, PhD
The Development of a Transplant-Independent Therapy for RPE Dysfunction
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Shintaro Shirahama, MD, PhD